This finding is in line with Chen et al.44 who found that patients with type II PD-L1+/TILs+ TME had a better tumor response to anti-PD-(L)1 therapy and another study in which patients with a higher IFN-γ signature score at baseline had relatively longer OS15. The gene discussed is SGCG; the disease is neoplasm.